Emerging Company Profile: Partnered with Novartis on a nanoparticle candidate for type 1 diabetes, Parvus develops its proprietary Navacims to help the body’s immune system differ between a pathogen and itself.
Canadian biotech Parvus Therapeutics Inc. believes it has a revolutionary approach to addressing a host of autoimmune diseases by essentially teaching the patient’s immune system to differentiate between a pathogen and itself so that the innate immune response does not cause off-target damage along with its therapeutic benefits.
Based in Calgary, Parvus stems from the research of Pere Santamaria, now the firm’s chief scientific officer and a board...
Highlights from day one of the BIO convention include advice for firms hoping to go public, a call for companies to push the US Congress on rare disease priority review vouchers, and updates on next-generation gene therapies.
Series B cash will be used to advance its Stargardt disease gene therapy.
The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.
New CEO Renée Aguiar-Lucander is marking her mark.
Supernus agreed to pay $561m upfront plus a contingent value right that could add $234m to buy Sage, topping a previously rejected offer from Biogen.
First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.
In this week's episode: breaking down big pharma’s executive pay; US vaccine panel upheaval; Merck’s RSV approval; MFN and Japan; and the future of Pfizer and Arvinas’s partnership.
